Clinical Trials
This section provides a regularly updated listing of late-stage clinical trials from www.clinicaltrials.gov that are of high relevance to clinicians who provide care to patients with psoriasis and psoriatic arthritis. Featured in the most recent updates are studies on traditional and biologic systemic therapies.
- July 1, 2011
- Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
- Condition: Ankylosing Spondylitis
Intervention:
Sponsors: Abbott; JSS Medical Research Inc.; CATO Research Canada
Recruiting - verified January 2012
- October 7, 2010
- A Study to Determine the Optimal Dose of SCH 900222 for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495 AM2) (MK-3222-003)
- Condition: Psoriasis
Interventions: Biological: SCH 900222; Biological: SCH 900222; Biological: SCH 900222; Biological: SCH 900222; Biological: Placebo
Sponsor: Schering-Plough
Active, not recruiting - verified January 2012
- September 14, 2010
- Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
- Condition: Moderate to Severe Plaque Psoriasis
Intervention:
Sponsor: Abbott
Recruiting - verified November 2011
- April 6, 2010
- Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis
- Condition: Psoriasis
Intervention: Drug: Etanercept
Sponsor: Pfizer
Recruiting - verified February 2012
- March 18, 2010
- A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
- Condition: Psoriasis
Interventions: Biological: ustekinumab/placebo; Biological: ustekinumab/placebo; Biological: ustekinumab/placebo
Sponsor: Centocor, Inc.
Recruiting - verified January 2012
- March 24, 2010
- Safety Study of Abatacept in Sweden
- Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Bristol-Myers Squibb; Karolinska Institutet
Active, not recruiting - verified February 2012
- March 15, 2010
- Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis
- Condition: Arthritis, Psoriatic
Interventions: Biological: CZP 200 mg Q2W; Biological: CZP 400 mg Q4W; Other: Placebo
Sponsor: UCB, Inc.
Active, not recruiting - verified February 2012
- February 25, 2010
- A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
- Condition: Arthritis, Psoriatic
Interventions: Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified February 2012
- November 26, 2008
- Chronic Plaque Psoriasis (Ps) Registry
- Condition: Chronic Plaque Psoriasis
Intervention: Biological: HUMIRA® (adalimumab)
Sponsor: Abbott
Recruiting - verified January 2012
- October 23, 2008
- Assessment of Long-Term Infliximab for Psoriasis (Study P05319)
- Condition: Psoriasis
Intervention: Biological: Infliximab
Sponsor: Schering-Plough
Active, not recruiting - verified January 2012
- July 27, 2007
- Psoriasis Longitudinal Assessment and Registry (PSOLAR)
- Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab; Drug: conventional systemic agents; Biological: infliximab
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified February 2012
